Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2016-06-27 Regulatory Filings
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Vitrolife introducerar EmbryoScope+ och breddar produktportföljen inom time-lapse
Regulatory Filings Classification · 99% confidence The document is explicitly titled "Pressmeddelande" (Press Release) and announces the introduction of a new product, EmbryoScope+, and the expansion of the product portfolio. It includes contact information, company background, and a concluding statement about the obligation to publish information according to securities market laws, dated June 27, 2016. This format strongly suggests a general corporate announcement rather than a specific financial filing like a 10-K, Earnings Release (ER), or Interim Report (IR). Since it is a general announcement that doesn't fit the specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which often captures general press releases required for market transparency, especially when the content is product/business focused rather than purely financial results or governance.
2016-06-27 Swedish
Vitrolife förvärvar OCTAX och MTG, världsledande inom laserteknologi för IVF
M&A Activity Classification · 98% confidence The document is explicitly titled "Pressmeddelande" (Press Release) and announces a significant corporate action: the acquisition of two companies (OCTAX and MTG). It details the financial terms, strategic rationale, and impact on the business. This type of announcement, detailing a major transaction like an acquisition, falls under the category of corporate actions or financing updates. Since the document is a press release announcing a major transaction (M&A activity), the most appropriate code is TAR (M&A Activity). It is not a formal regulatory filing like a 10-K, nor is it a simple announcement of a report (RPA/RNS), but rather the substance of the news itself. The text also mentions future presentations of the acquisition during the interim report call and Capital Markets Day, confirming this is the primary announcement document.
2016-06-01 Swedish
Vitrolife acquiring OCTAX and MTG, jointly holding a world-leading position in laser technology for IVF
M&A Activity Classification · 98% confidence The document is a 'Press Release' dated June 1, 2016, announcing that Vitrolife AB has completed the acquisition of two companies (OCTAX and MTG). This type of announcement details a significant corporate transaction, specifically a merger or acquisition (M&A). Based on the provided definitions, the most appropriate category is 'M&A Activity' (Code: TAR). Although it mentions future presentations at the Interim Report release and Capital Markets Day, the primary content is the completion of the transaction itself, not the announcement of a report (RPA) or the report itself (10-K, IR).
2016-06-01 English
Report from Annual General Meeting of Vitrolife AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Report from Annual General Meeting of Vitrolife AB (publ)' and details decisions made at the meeting, such as dividend approval, board re-election, remuneration, and authorizations granted. This directly corresponds to the definition of 'AGM Information' (Code: AGM-R). Although it contains dividend information (DIV) and remuneration details (DEF 14A), the overarching context is the summary of the AGM proceedings.
2016-04-29 English
Kommuniké från årsstämma i Vitrolife AB (publ)
AGM Information Classification · 99% confidence The document is titled 'Kommuniké från årsstämma i Vitrolife AB (publ)' (Communication from the Annual General Meeting in Vitrolife AB (publ)) and details the resolutions passed at the AGM held on April 28th, including dividend approval, board re-elections, remuneration, and authorizations for share issuance/repurchase. This content directly relates to the formal proceedings and outcomes of the Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary/communication of the results, not a proxy statement (PSI) or a full voting result declaration (DVA), but rather the official summary of the meeting's decisions.
2016-04-29 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report ('delårsrapport') for Vitrolife AB covering the period January-March 2016. It contains detailed financial statements, key performance indicators (EBITDA, net sales, net income), management commentary, and segment reporting. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2016
2016-04-26 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.